tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2018 Sep 11. doi: 10.1080/21645515.2018.1520580. [Epub ahead of print]
[h=1]Canadian older adults' perceptions of effectiveness and value of regular and high-dose influenza vaccines.[/h] Pereira JA[SUP]1[/SUP], Gilca V[SUP]2[/SUP], Waite N[SUP]3[/SUP], Andrew MK[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza vaccination is an important public health intervention for older adults, yet vaccination rates remain suboptimal. We conducted an online survey of Canadians ≥ 65 years to explore satisfaction with publicly-funded standard-dose influenza vaccines, and perceptions of the need for a more effective product. They were provided with information about currently approved influenza vaccines, and were asked about their preferences should all formulations be available for free, and should the recently approved high-dose (HD) vaccine for seniors be available at a cost. From March to April 2017, 5014 seniors completed the survey; mean age was 71.3 ? 5.17 years, 50% were female, and 42.6% had one or more chronic conditions. 3403 (67.9%) had been vaccinated against influenza in the 2016/17 season. Of all respondents, 3460 (69%) were satisfied with the standard-dose influenza vaccines, yet 3067 (61.1%) thought that a more effective vaccine was/may be needed. If HD was only available at a cost, 1426 (28.4%) respondents would consider it, of whom 62.9% would pay $20 or less. If all vaccines were free next season, 1914 (38.2%) would opt for HD (including 12.2% of those who previously rejected influenza vaccines), 856 (17.1%) would choose adjuvanted vaccine, and 558 (11.1%) standard-dose vaccine. 843 (16.8%) of respondents were against vaccines, 451 (9.0%) had no preference and 392 (7.8%) were uncertain. Making this product available through publicly funded programs may be a strategy to increase immunization rates in this population.
[h=4]KEYWORDS:[/h] Influenza; Survey; Vaccines; decision-making; seniors; willingness-to-pay
PMID: 30204043 DOI: 10.1080/21645515.2018.1520580
[h=1]Canadian older adults' perceptions of effectiveness and value of regular and high-dose influenza vaccines.[/h] Pereira JA[SUP]1[/SUP], Gilca V[SUP]2[/SUP], Waite N[SUP]3[/SUP], Andrew MK[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza vaccination is an important public health intervention for older adults, yet vaccination rates remain suboptimal. We conducted an online survey of Canadians ≥ 65 years to explore satisfaction with publicly-funded standard-dose influenza vaccines, and perceptions of the need for a more effective product. They were provided with information about currently approved influenza vaccines, and were asked about their preferences should all formulations be available for free, and should the recently approved high-dose (HD) vaccine for seniors be available at a cost. From March to April 2017, 5014 seniors completed the survey; mean age was 71.3 ? 5.17 years, 50% were female, and 42.6% had one or more chronic conditions. 3403 (67.9%) had been vaccinated against influenza in the 2016/17 season. Of all respondents, 3460 (69%) were satisfied with the standard-dose influenza vaccines, yet 3067 (61.1%) thought that a more effective vaccine was/may be needed. If HD was only available at a cost, 1426 (28.4%) respondents would consider it, of whom 62.9% would pay $20 or less. If all vaccines were free next season, 1914 (38.2%) would opt for HD (including 12.2% of those who previously rejected influenza vaccines), 856 (17.1%) would choose adjuvanted vaccine, and 558 (11.1%) standard-dose vaccine. 843 (16.8%) of respondents were against vaccines, 451 (9.0%) had no preference and 392 (7.8%) were uncertain. Making this product available through publicly funded programs may be a strategy to increase immunization rates in this population.
[h=4]KEYWORDS:[/h] Influenza; Survey; Vaccines; decision-making; seniors; willingness-to-pay
PMID: 30204043 DOI: 10.1080/21645515.2018.1520580